Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down – Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) gapped down before the market opened on Wednesday . The stock had previously closed at $39.75, but opened at $32.72. Supernus Pharmaceuticals shares last traded at $34.98, with a volume of 255,949 shares trading hands.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $57.00 to $36.00 in a research report on Wednesday.

Supernus Pharmaceuticals Stock Down 16.2 %

The company has a market cap of $1.84 billion, a P/E ratio of 31.25 and a beta of 0.90. The company has a 50 day moving average price of $37.64 and a 200-day moving average price of $35.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 9.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SUPN. Barclays PLC lifted its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $791,000. Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Franklin Resources Inc. increased its stake in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth $1,498,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.